ClinicalTrials.gg
CompletedNCT04887948Updated Dec 14, 2022Results posted

Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

A Phase 3 interventional study of 20-valent pneumococcal conjugate vaccine (20vPnC) and BNT162b2 in Pneumococcal Disease, COVID-19 and SARS-CoV-2 Infection, sponsored by Pfizer. Completed at 27 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-14.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
570
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
11th of 19
570 · median 668
Started
2021
with 1 other
Phase 3
14 of 19
1 open now
Registered
10th of 19
by date
Lead sponsor
16 of 19
Pfizer

Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 11th largest by enrollment, is one of 2 that started in 2021, is one of 14 in phase 3, and was the 10th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Pneumococcal 20-Valent Conjugate Vaccine

Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone

03

Conditions studied

  • Pneumococcal Disease
  • COVID-19
  • SARS-CoV-2 Infection
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants ≥65 years of age at the time of consent
  • Participating or participated in Study C4591001, received 2 doses of 30 µg BNT162b2 with the second dose given ≥6 months prior to the first vaccination in this study, and have not received a third dose of BNT162b2
  • Adults determined by clinical assessment, including medical history and clinical judgement, to be eligible for the study, including adults with preexisting stable disease
  • Adults who have no history of ever receiving a pneumococcal vaccine, or received a licensed pneumococcal vaccination ≥12 months prior to the first vaccination in this study

Exclusion criteria

Exclusion Criteria:

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis)
  • Serious chronic disorder that in the investigator's opinion would make the participant inappropriate for entry into the study
  • Previous clinical or microbiological diagnosis of COVID-19
  • Previous vaccination with any pneumococcal vaccine, or planned receipt of any licensed or investigational pneumococcal vaccine through study participation
  • Previous vaccination with any coronavirus vaccine, other than those received in Study C4591001
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
570 participants (actual)

Study arms

  • Experimental
    Coadministration Group

    Participants receive an injection of pneumococcal vaccine (20vPnC) and of COVID-19 vaccine (BNT162b2) at the same visit.

    Biological: 20-valent pneumococcal conjugate vaccine (20vPnC) · Biological: BNT162b2

  • Active comparator
    20vPnC-only Group

    Participants receive an injection of pneumococcal vaccine (20vPnC) and of saline at the same visit.

    Biological: 20-valent pneumococcal conjugate vaccine (20vPnC) · Other: Saline

  • Active comparator
    BNT162b2-only Group

    Participants receive an injection of COVID-19 vaccine (BNT162b2) and of saline at the same visit.

    Biological: BNT162b2 · Other: Saline

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Local Reactions at Each Injection Site Within 10 Days After Vaccination

    Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\>) 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prevented daily activity. Percentage of participants with local reactions at each injection site within 10 days after vaccination and the associated 2-sided 95% confidence interval (CI) based on the Clopper and Pearson method was presented.

    Time frame: Within 10 days after vaccination

  2. Percentage of Participants With Systemic Events Within 7 Days After Vaccination

    Systemic events including fever, fatigue, headache, chills, muscle pain and joint pain were recorded by participants using an e-diary. Fever was defined as temperature \>=38.0 degree Celsius (C) and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, chills, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Percentage of participants with systemic events within 7 days after vaccination and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented.

    Time frame: Within 7 days after vaccination

  3. Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants with AEs and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From day of vaccination (Day 1) up to 1 month after vaccination

  4. Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination

    A SAE was defined as any untoward medical occurrence that, at any dose, resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or that was considered to be an important medical event. Percentage of participants with SAEs and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented.

    Time frame: From day of vaccination (Day 1) up to 6 months after vaccination

Secondary outcomes

  1. Geometric Mean Titers (GMTs) of Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) at 1 Month After Vaccination With 20vPnC

    OPA titers were measured from serum samples for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F,8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the OPA titers and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and 20vPnC only group (20vPnC + saline) as specified in protocol.

    Time frame: 1 month after vaccination with 20vPnC

  2. Geometric Mean Concentration (GMC) of Full-Length S-Binding Immunoglobulin G (IgG) Levels at 1 Month After Vaccination With BNT162b2

    IgG levels were measured in serum samples using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length S-binding assay. GMCs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and BNT162b2 only group (BNT162b2 + saline) as specified in protocol.

    Time frame: 1 month after vaccination with BNT162b2

  3. Geometric Mean Fold Rise (GMFR) of Full-Length S-Binding IgG Levels From Before Vaccination to 1 Month After Vaccination With BNT162b2

    The GMFR for each vaccine group was defined as the geometric mean of the fold rises in the assay results from before to approximately 1 month after vaccination. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and BNT162b2 only group (BNT162b2 + saline) as specified in the protocol.

    Time frame: Before vaccination to 1 month after vaccination with BNT162b2

07

Results

Posted Dec 14, 2022

Participant flow

Eligible participants who received 2 doses of ribonucleic acid (RNA)-based COVID-19 vaccine (BNT162b2) at least 6 months previously in study C4591001 (NCT04368728) were stratified by prior pneumococcal vaccine status (no previous pneumococcal vaccine \[naïve\] or receipt of at least 1 dose of a pneumococcal vaccine \[experienced\]) and randomized to 1 of the 3 vaccine groups in this study.

Participant flow — Overall Study
MilestoneCoadministration Group: 20vPnC+BNT162b220vPnC Only Group: 20vPnC+SalineBNT162b2 Only Group: BNT162b2+Saline
Started190191189
Vaccinated187187185
Completed184177182
Not completed6147
Withdrew: Death100
Withdrew: Lost to follow-up103
Withdrew: Physician decision041
Withdrew: Protocol violation110
Withdrew: Withdrawal by subject061
Withdrew: No longer met eligibility criteria121
Withdrew: Other211

Outcome measures

PrimaryPercentage of Participants With Local Reactions at Each Injection Site Within 10 Days After Vaccination

Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\>) 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prevented daily activity. Percentage of participants with local reactions at each injection site within 10 days after vaccination and the associated 2-sided 95% confidence interval (CI) based on the Clopper and Pearson method was presented.

Time frame:
Within 10 days after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions at Each Injection Site Within 10 Days After Vaccination
Percentage of participantsCoadministration Group (20vPnC+BNT162b2): 20vPnC Vaccination SiteCoadministration Group (20vPnC+BNT162b2): BNT162b2 Vaccination Site20vPnC Only Group (20vPnC+Saline): 20vPnC Vaccination Site20vPnC Only Group (20vPnC+Saline): Saline Vaccination SiteBNT162b2 Only Group (BNT162b2+Saline): BNT162b2 Vaccination SiteBNT162b2 Only Group (BNT162b2+Saline): Saline Vaccination Site
Redness: Any8.6 (5.0 to 13.7)9.7 (5.9 to 14.9)8.1 (4.6 to 13.0)0.0 (0.0 to 2.0)9.7 (5.9 to 14.9)2.7 (0.9 to 6.2)
Redness: Mild5.9 (3.0 to 10.4)5.9 (3.0 to 10.4)4.3 (1.9 to 8.3)0.0 (0.0 to 2.0)6.5 (3.4 to 11.1)2.2 (0.6 to 5.4)
Redness: Moderate2.7 (0.9 to 6.2)3.2 (1.2 to 6.9)3.2 (1.2 to 6.9)0.0 (0.0 to 2.0)2.7 (0.9 to 6.2)0.5 (0.0 to 3.0)
Redness: Severe0.0 (0.0 to 2.0)0.5 (0.0 to 3.0)0.5 (0.0 to 3.0)0.0 (0.0 to 2.0)0.5 (0.0 to 3.0)0.0 (0.0 to 2.0)
Swelling: Any8.1 (4.6 to 13.0)9.7 (5.9 to 14.9)8.6 (5.0 to 13.6)0.0 (0.0 to 2.0)11.4 (7.2 to 16.8)1.1 (0.1 to 3.9)
Swelling: Mild5.4 (2.6 to 9.7)5.9 (3.0 to 10.4)5.4 (2.6 to 9.7)0.0 (0.0 to 2.0)6.5 (3.4 to 11.1)0.0 (0.0 to 2.0)
Swelling: Moderate2.7 (0.9 to 6.2)3.8 (1.5 to 7.6)3.2 (1.2 to 6.9)0.0 (0.0 to 2.0)4.9 (2.2 to 9.0)1.1 (0.1 to 3.9)
Swelling: Severe0.0 (0.0 to 2.0)0.0 (0.0 to 2.0)0.0 (0.0 to 2.0)0.0 (0.0 to 2.0)0.0 (0.0 to 2.0)0.0 (0.0 to 2.0)
Pain at injection site: Any73.0 (66.0 to 79.2)72.4 (65.4 to 78.7)60.2 (52.8 to 67.3)9.7 (5.8 to 14.9)67.6 (60.3 to 74.3)16.8 (11.7 to 22.9)
Pain at injection site: Mild55.1 (47.7 to 62.4)56.8 (49.3 to 64.0)52.2 (44.7 to 59.5)9.7 (5.8 to 14.9)50.3 (42.8 to 57.7)16.2 (11.2 to 22.3)
Pain at injection site: Moderate17.8 (12.6 to 24.1)15.7 (10.8 to 21.7)7.0 (3.8 to 11.7)0.0 (0.0 to 2.0)17.3 (12.1 to 23.5)0.5 (0.0 to 3.0)
Pain at injection site: Severe0.0 (0.0 to 2.0)0.0 (0.0 to 2.0)1.1 (0.1 to 3.8)0.0 (0.0 to 2.0)0.0 (0.0 to 2.0)0.0 (0.0 to 2.0)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination

Systemic events including fever, fatigue, headache, chills, muscle pain and joint pain were recorded by participants using an e-diary. Fever was defined as temperature \>=38.0 degree Celsius (C) and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, chills, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Percentage of participants with systemic events within 7 days after vaccination and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented.

Time frame:
Within 7 days after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination
Percentage of participantsCoadministration Group: 20vPnC+BNT162b220vPnC Only Group: 20vPnC+SalineBNT162b2 Only Group: BNT162b2+Saline
Fever: >=38.0 degree C13.0 (8.5 to 18.7)1.1 (0.1 to 3.8)8.6 (5.0 to 13.7)
Fever: >=38.0 degree C to 38.4 degree C7.0 (3.8 to 11.7)0.5 (0.0 to 3.0)2.7 (0.9 to 6.2)
Fever: >38.4 degree C to 38.9 degree C5.4 (2.6 to 9.7)0.5 (0.0 to 3.0)4.9 (2.2 to 9.0)
Fever: >38.9 degree C to 40.0 degree C0.5 (0.0 to 3.0)0.0 (0.0 to 2.0)1.1 (0.1 to 3.9)
Fever: >40.0 degree C0.0 (0.0 to 2.0)0.0 (0.0 to 2.0)0.0 (0.0 to 2.0)
Fatigue: Any54.1 (46.6 to 61.4)36.0 (29.1 to 43.4)54.6 (47.1 to 61.9)
Fatigue: Mild17.8 (12.6 to 24.1)23.7 (17.7 to 30.4)27.0 (20.8 to 34.0)
Fatigue: Moderate33.0 (26.3 to 40.3)12.4 (8.0 to 18.0)24.9 (18.8 to 31.7)
Fatigue: Severe3.2 (1.2 to 6.9)0.0 (0.0 to 2.0)2.7 (0.9 to 6.2)
Headache: Any30.3 (23.7 to 37.4)17.2 (12.1 to 23.4)33.0 (26.3 to 40.3)
Headache: Mild17.8 (12.6 to 24.1)14.5 (9.8 to 20.4)24.9 (18.8 to 31.7)
Headache: Moderate11.9 (7.6 to 17.4)2.7 (0.9 to 6.2)7.6 (4.2 to 12.4)
Headache: Severe0.5 (0.0 to 3.0)0.0 (0.0 to 2.0)0.5 (0.0 to 3.0)
Chills: Any26.5 (20.3 to 33.5)7.0 (3.8 to 11.7)22.2 (16.4 to 28.8)
Chills: Mild18.4 (13.1 to 24.7)5.9 (3.0 to 10.3)12.4 (8.0 to 18.1)
Chills: Moderate6.5 (3.4 to 11.1)1.1 (0.1 to 3.8)7.6 (4.2 to 12.4)
Chills: Severe1.6 (0.3 to 4.7)0.0 (0.0 to 2.0)2.2 (0.6 to 5.4)
Muscle pain: Any32.4 (25.7 to 39.7)14.5 (9.8 to 20.4)31.9 (25.2 to 39.1)
Muscle pain: Mild17.3 (12.1 to 23.5)10.2 (6.3 to 15.5)15.7 (10.8 to 21.7)
Muscle pain: Moderate14.1 (9.4 to 19.9)4.3 (1.9 to 8.3)15.1 (10.3 to 21.1)
Muscle pain: Severe1.1 (0.1 to 3.9)0.0 (0.0 to 2.0)1.1 (0.1 to 3.9)
Joint pain: Any26.5 (20.3 to 33.5)9.1 (5.4 to 14.2)24.9 (18.8 to 31.7)
Joint pain: Mild15.1 (10.3 to 21.1)5.4 (2.6 to 9.7)15.1 (10.3 to 21.1)
Joint pain: Moderate11.4 (7.2 to 16.8)3.8 (1.5 to 7.6)9.7 (5.9 to 14.9)
Joint pain: Severe0.0 (0.0 to 2.0)0.0 (0.0 to 2.0)0.0 (0.0 to 2.0)
PrimaryPercentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants with AEs and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From day of vaccination (Day 1) up to 1 month after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination
Percentage of participantsCoadministration Group: 20vPnC+BNT162b220vPnC Only Group: 20vPnC+SalineBNT162b2 Only Group: BNT162b2+Saline
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination5.3 (2.6 to 9.6)4.3 (1.9 to 8.3)6.5 (3.4 to 11.1)
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination

A SAE was defined as any untoward medical occurrence that, at any dose, resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or that was considered to be an important medical event. Percentage of participants with SAEs and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented.

Time frame:
From day of vaccination (Day 1) up to 6 months after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination
Percentage of participantsCoadministration Group: 20vPnC+BNT162b220vPnC Only Group: 20vPnC+SalineBNT162b2 Only Group: BNT162b2+Saline
Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination0.5 (0.0 to 2.9)1.1 (0.1 to 3.8)2.7 (0.9 to 6.2)
SecondaryGeometric Mean Titers (GMTs) of Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) at 1 Month After Vaccination With 20vPnC

OPA titers were measured from serum samples for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F,8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the OPA titers and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and 20vPnC only group (20vPnC + saline) as specified in protocol.

Time frame:
1 month after vaccination with 20vPnC
Reported as:
Geometric mean · Titer
Geometric Mean Titers (GMTs) of Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) at 1 Month After Vaccination With 20vPnC
TiterCoadministration Group: 20vPnC+BNT162b220vPnC Only Group: 20vPnC+Saline
Serotype 1142 (116 to 176)131 (106 to 162)
Serotype 349 (42 to 56)52 (44 to 61)
Serotype 4609 (484 to 766)573 (447 to 734)
Serotype 581 (65 to 100)98 (80 to 120)
Serotype 6A1377 (1058 to 1792)1317 (1042 to 1665)
Serotype 6B1449 (1153 to 1821)1478 (1207 to 1810)
Serotype 7F977 (836 to 1142)1102 (951 to 1275)
Serotype 8299 (235 to 381)344 (274 to 431)
Serotype 9V1722 (1365 to 2172)1531 (1210 to 1936)
Serotype 10A2252 (1751 to 2898)2644 (2023 to 3456)
Serotype 11A1875 (1414 to 2488)1932 (1445 to 2583)
Serotype 12F2165 (1668 to 2809)2211 (1695 to 2885)
Serotype 14709 (572 to 879)640 (528 to 775)
Serotype 15B1520 (1092 to 2117)1852 (1377 to 2491)
Serotype 18C1059 (869 to 1290)846 (684 to 1046)
Serotype 19A637 (520 to 781)530 (436 to 644)
Serotype 19F305 (242 to 383)377 (299 to 476)
Serotype 22F5225 (3931 to 6943)4464 (3354 to 5942)
Serotype 23F336 (251 to 450)385 (283 to 524)
Serotype 33F4907 (3813 to 6316)5544 (4234 to 7261)
SecondaryGeometric Mean Concentration (GMC) of Full-Length S-Binding Immunoglobulin G (IgG) Levels at 1 Month After Vaccination With BNT162b2

IgG levels were measured in serum samples using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length S-binding assay. GMCs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and BNT162b2 only group (BNT162b2 + saline) as specified in protocol.

Time frame:
1 month after vaccination with BNT162b2
Reported as:
Geometric mean · Units per milliliter
Geometric Mean Concentration (GMC) of Full-Length S-Binding Immunoglobulin G (IgG) Levels at 1 Month After Vaccination With BNT162b2
Units per milliliterCoadministration Group: 20vPnC+BNT162b2BNT162b2 Only Group: BNT162b2+Saline
Geometric Mean Concentration (GMC) of Full-Length S-Binding Immunoglobulin G (IgG) Levels at 1 Month After Vaccination With BNT162b229114 (26120 to 32451)26655 (24003 to 29599)
SecondaryGeometric Mean Fold Rise (GMFR) of Full-Length S-Binding IgG Levels From Before Vaccination to 1 Month After Vaccination With BNT162b2

The GMFR for each vaccine group was defined as the geometric mean of the fold rises in the assay results from before to approximately 1 month after vaccination. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and BNT162b2 only group (BNT162b2 + saline) as specified in the protocol.

Time frame:
Before vaccination to 1 month after vaccination with BNT162b2
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFR) of Full-Length S-Binding IgG Levels From Before Vaccination to 1 Month After Vaccination With BNT162b2
Fold riseCoadministration Group: 20vPnC+BNT162b2BNT162b2 Only Group: BNT162b2+Saline
Geometric Mean Fold Rise (GMFR) of Full-Length S-Binding IgG Levels From Before Vaccination to 1 Month After Vaccination With BNT162b235.5 (30.9 to 40.7)39.0 (33.5 to 45.5)

Adverse events

Collected over Systematic assessment: local reactions recorded within 10 days after vaccination, and systemic events recorded within 7 days after vaccination; Non-systematic assessment: SAEs recorded from day of vaccination (Day 1) up to 6 months after vaccination and other AEs recorded from Day 1 up to 1 month after vaccination. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Coadministration Group: 20vPnC+BNT162b21/187 (0.5%)1/187 (0.5%)157/187 (84%)
20vPnC Only Group: 20vPnC+Saline0/187 (0%)2/187 (1.1%)137/187 (73.3%)
BNT162b2 Only Group: BNT162b2+Saline0/185 (0%)5/185 (2.7%)149/185 (80.5%)
Most frequent serious events
Most frequent serious events
EventCoadministration Group: 20vPnC+BNT162b220vPnC Only Group: 20vPnC+SalineBNT162b2 Only Group: BNT162b2+Saline
Femur fractureInjury, poisoning and procedural complications0/1870/1871/185
Breast cancer stage INeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1870/1871/185
Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1870/1871/185
Metastases to liverNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1870/1871/185
Small intestine carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1870/1871/185
Acute kidney injuryRenal and urinary disorders0/1870/1871/185
Angina unstableCardiac disorders0/1871/1870/185
Duodenal perforationGastrointestinal disorders1/1870/1870/185
GlioblastomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1871/1870/185
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCoadministration Group: 20vPnC+BNT162b220vPnC Only Group: 20vPnC+SalineBNT162b2 Only Group: BNT162b2+Saline
Injection site pain (PAIN)General disorders146/187115/187133/185
Fatigue (FATIGUE)General disorders100/18767/187101/185
Headache (HEADACHE)Nervous system disorders56/18732/18761/185
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders60/18727/18759/185
Chills (CHILLS)General disorders49/18713/18741/185
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders49/18717/18746/185
Injection site erythema (REDNESS)General disorders26/18715/18722/185
Injection site swelling (SWELLING)General disorders26/18716/18721/185
Pyrexia (FEVER)General disorders24/1872/18716/185
Urinary tract infectionInfections and infestations2/1870/1871/185

Baseline characteristics

Safety population included all participants who received at least 1 dose of the study intervention and had safety follow-up after vaccination.

Age, Continuous
Age, Continuous(Years)Coadministration Group: 20vPnC+BNT162b220vPnC Only Group: 20vPnC+SalineBNT162b2 Only Group: BNT162b2+SalineTotal
Mean71.0 ± 4.2271.8 ± 4.9471.8 ± 4.9571.5 ± 4.72
Sex: Female, Male
Sex: Female, Male(Participants)Coadministration Group: 20vPnC+BNT162b220vPnC Only Group: 20vPnC+SalineBNT162b2 Only Group: BNT162b2+SalineTotal
Female897577241
Male98112108318
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Coadministration Group: 20vPnC+BNT162b220vPnC Only Group: 20vPnC+SalineBNT162b2 Only Group: BNT162b2+SalineTotal
Hispanic or Latino28262579
Not Hispanic or Latino159161160480
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Coadministration Group: 20vPnC+BNT162b220vPnC Only Group: 20vPnC+SalineBNT162b2 Only Group: BNT162b2+SalineTotal
American Indian or Alaska Native0112
Asian105924
Native Hawaiian or Other Pacific Islander0000
Black or African American871025
White164172165501
More than one race4206
Unknown or Not Reported1001
08

Study locations

27 sites
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Alliance for Multispecialty Research, LLC
    Coral Gables, Florida 33134, United States
  • Indago Research & Health Center, Inc
    Hialeah, Florida 33012, United States
  • Research Centers of America ( Hollywood )
    Hollywood, Florida 33024, United States
  • Acevedo Clinical Research Associates
    Miami, Florida 33142, United States
  • Clinical Neuroscience Solutions
    Orlando, Florida 32801, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Alliance for Multispecialty Research, LLC
    Newton, Kansas 67114, United States
  • Clinical Research Professionals
    Chesterfield, Missouri 63005, United States
  • Sundance Clinical Research
    Saint Louis, Missouri 63141, United States
  • Meridian Clinical Research, LLC
    Omaha, Nebraska 68134, United States
  • Meridian Clinical Research, LLC
    Endwell, New York 13760, United States
  • Accellacare - Wilmington
    Wilmington, North Carolina 28401, United States
  • Aventiv Research Inc
    Columbus, Ohio 43213, United States
  • Alliance for Multispecialty Research, LLC
    Knoxville, Tennessee 37909, United States
  • Clinical Neuroscience Solutions, Inc. dba CNS Healthcare
    Memphis, Tennessee 38119, United States
  • Benchmark Research
    Austin, Texas 78705, United States
  • IMA Clinical Research San Antonio
    San Antonio, Texas 78229, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
  • Martin Diagnostic Clinic
    Tomball, Texas 77375, United States
  • Martins Diagnostic Clinic
    Tomball, Texas 77375, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
  • Wenatchee Valley Hospital
    Wenatchee, Washington 98801, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Dec 2021, 6 months.

Results were first posted in Dec 2022, 1 year after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 6 months is below that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2021
First posted
May 14, 2021
StartActual
May 20, 2021
Primary completionActual
Dec 8, 2021
CompletionActual
Dec 8, 2021
Results first posted
Dec 14, 2022
Last update
Dec 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04887948
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 14, 2021
Start date
May 20, 2021
Primary completion
Dec 8, 2021
Completion
Dec 8, 2021
Results posted
Dec 14, 2022
Last update
Dec 14, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pneumococcal 20-Valent Conjugate Vaccine · BNT162 Vaccine

Start the discussion